Januvia Sales Data
| Rank 14 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Januvia U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 14 ( 1) |
$700,941 | 3.63% | 2,168 | -2.78% |
| Q3 2013 | 15 ( 1) |
$676,400 | -2.33% | 2,230 | -6.26% |
| Q2 2013 | 14 | $692,528 | -1.23% | 2,379 | 0.04% |
| Q1 2013 | 14 (1) |
$701,126 | 6.40% | 2,378 | 0.38% |
| Q4 2012 | 15 | $658,957 | 1.18% | 2,369 | 1.89% |
| Q3 2012 | 15 (4) |
$651,299 | 7.50% | 2,325 | 1.17% |
| Q2 2012 | 19 (3) |
$605,840 | 3.81% | 2,298 | 3.19% |
| Q1 2012 | 22 (1) |
$583,603 | 7.89% | 2,227 | 4.41% |
| Q4 2011 | 23 (1) |
$540,947 | 4.87% | 2,133 | 4.35% |
| Q3 2011 | 24 | $515,840 | 1.19% | 2,044 | 0.79% |
| Q2 2011 | 24 (3) |
$509,786 | 8.81% | 2,028 | 3.89% |
| Q1 2011 | 27 | $468,525 | n/a | 1,952 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
Related news
| Date | Article |
|---|---|
| August 12, 2022 | FDA: Common Diabetes Drug Januvia May Contain Traces of Carcinogen |
| August 12, 2022 | Common Diabetes Drug Januvia May Contain Traces of Carcinogen, FDA Says |
